PRME News and Press, First Trust Heitman Global Prime Real Estate ETF From 12/01/23

2023-12-01 14:45:50 ET Summary AI isn't just revolutionizing biotech; it's reinventing it. From predicting diseases to accelerating drug discovery, AI is turning data into medical gold, reshaping how we approach healthcare innovation. AI is turbocharging techniques like CRISPR and...

2023-11-30 07:45:00 ET Cathie Wood, founder and CEO of Ark Invest, has a unique approach to investing. She targets companies that are creating and applying disruptive technologies in fields such as artificial intelligence (AI), autonomous vehicles, genomics, and biotech. These companies hav...

Prime Medicine Inc. (PRME) is expected to report $-0.45 for Q3 2023

2023-11-03 17:37:01 ET Prime Medicine ( NASDAQ: PRME ) on Friday filed a prospectus for a mixed securities shelf offering of up to $500M. This prospectus is not an offer to sell these securities. SEC Filing For further details see: Prime Medicine files f...

2023-11-03 16:16:51 ET More on Prime Medicine Prime Medicine: Not Yet Primed For Retail Investment Gene editing stocks gain after Eli Lilly deal amid FDA AdCom Seeking Alpha’s Quant Rating on Prime Medicine Historical earnings data for Prime Medicine ...

-- Presented new preclinical research across multiple programs, including proof-of-concept data from in vivo rodent and large animal studies, as well as updates on proprietary delivery systems -- -- Shared detailed safety evaluation of lead Prime Editors across multiple programs; prel...

2023-11-03 15:23:43 ET More on XBI and IBB Biopharma Bounce-Back: From Policy Pains To Profitable Plains IBB: The Illness Of Idiosyncratic Risk Jefferies is bullish on XBI at around $70 for year-end and first quarter 2024 returns Citi turns cautious on pharma...

2023-10-31 12:46:31 ET More on Eli Lilly Albemarle Vs. Eli Lilly: 1 Potentially Set To Soar And 1 Bubble Stock To Ignore Eli Lilly: The GLP-1 Opportunity, While Increasingly Recognized, Is Vastly Underestimated Eli Lilly: Do Not Chase This Stock Over The Cliff ...

Up to 83% of Hepatocytes (up to 50% whole liver) Precisely Edited for p.L358fs Mutation Following IV Infusion of Prime Editor in NHPs with No Safety Concerns Observed; Editing Well Above Anticipated Threshold Necessary to Reverse Disease Manifestations Up to 56% Whole Liver Editing Obse...

New In Vivo Data in Humanized Mouse Model Demonstrate that Prime Editing Can Correct Predominant Mutations Accounting for Approximately 60% of Patients with RHO adRP Up to 70% Precise Correction at RHO p.P23H Mutation and up to 65% at RHO p.V345L and p.P347L, Well Above Threshold Requir...